Navigation Links
Cappella Inc. Secures $17.3 Million Series C Investment
Date:6/14/2009

- New and existing investors complete a $17.3 million Series C investment

- Experienced medical device executive, Dr. Art Rosenthal, appointed as CEO

- Aggressive launch of Sideguard(TM) Sidebranch stent in EU following recent CE Marking

- Expansion of management team, R&D and manufacturing capacity in Galway, Ireland

WILMINGTON, Del. and GALWAY, Ireland, June 15 /PRNewswire/ -- Cappella, Inc. (Cappella) announces today that it has completed a $17.3 million Series C investment, led by new investors, Fountain Healthcare Partners and Mitsui & Co. Venture Partners (MCVP). Enterprise Ireland also participated in this round alongside Cappella's existing investors, Polytechnos Partners and ACT Venture Capital.

Proceeds will be used to finance the launch of Cappella's proprietary Sideguard(TM) Sidebranch stent for the treatment of Bifurcated Vascular Disease in Europe and to advance key R&D programs in Galway on additional applications of Cappella's technology in Complex Coronary Artery Disease (CAD).

Commenting on this financing, Dr. Art Rosenthal, Cappella's recently appointed CEO, said "This funding will allow us to expand our pipeline, to supplement on-going clinical studies and to successfully launch our first product, the Sideguard(TM) Sidebranch stent. We believe our proprietary products will treat many types of bifurcation disease, including Left Main Bifurcation Disease. In 2008, this was a $1.0 billion worldwide market and it is growing annually."

Dr Rosenthal previously served as Chairman and CEO of Labcoat Ltd. and as Chief Scientific Officer of Boston Scientific Corporation. Cappella has also appointed additional senior management to lead European sales and manufacturing activities.

Dr Ena Prosser of Fountain Healthcare Partners commented: "We are delighted to invest in Cappella at a very strategi
'/>"/>

SOURCE Cappella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
2. Hyperion Therapeutics Secures $40 Million In Series B Round
3. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
4. Altheus Therapeutics Secures $3.6 Million in Venture Capital
5. Apollo Endosurgery, Inc. Secures $11.5 Million in Series A Financing.
6. Dendreon Secures $130 Million Committed Equity Financing Facility
7. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
8. Taligen Therapeutics Secures Series B Financing
9. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
10. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
11. Amarin Secures Global Intellectual Property Rights for Lipid Programs

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...EW YORK, Nov. 30 The Mi...MJFF) today announced $1.5 million in total awards...lly disease-modifying therapies for Parkinson,s di...proaches to Drug Discovery for Parkinson,s Disease...oration, plc (NYSE: ELN ), a neuroscience-based ...
(Date:11/30/2009)... CHANGCHUN, China and LOS ANGELES, Nov. 30 /PR...uticals, Inc. (OTC Bulletin Board: CYXN; ,China Yo...g manufacturer, distributor and,retailer of pharma...t has,completed preparation for distribution of me... Chinese government recently formalized the nation...
(Date:11/30/2009)...BOSTON and COPENHAGEN, Nov. 30 Exi...oday that the Harvard Medical School ICCB-Longwood...s a MicroRNA Screening Center of Excellence. ICCB...l, and associated hospitals and institutions, for ...Ai libraries. ,, MicroRNAs are a novel class of...
(Date:11/28/2009)... The Vanuatu National Advisory Committe...ional Communication (SNC) Project in collaboration...systems Ltd. of New Zealand have generated prelimi...t will form the background for the country’s...vention on Climate Change (UNFCCC). , ...
Breaking Biology Technology:The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4
...ship Completes CTI,s Transformation to Commercial ... SEATTLE, April 24 Cell Therapeutics, Inc.,(Nasd...ilips, most recently,Vice President and General Ma... President of CTI with direct responsibilities for...ive August 1, 2008. Philips, responsibilities,will...
... April 23 Anadys Pharmaceuticals,Inc. (Nasdaq: A...arter 2008,financial results on Wednesday, April 3... Anadys will hold a conference call and webcast to...and highlights and to provide an update on,its dev...5:00 p.m. Eastern,Daylight Time. A live webcast of...
...iz., April 23 ImaRx Therapeutics,Inc. (Nasdaq: I...agreement,with Abbott Laboratories pursuant to whi...million non-recourse promissory note with Abbott i...ase. As a result, full title to,the urokinase asse...product, all regulatory and clinical documentation...
Other Biology Technology:Veteran Drug Industry Executive to Become President of CTI 2Veteran Drug Industry Executive to Become President of CTI 3Veteran Drug Industry Executive to Become President of CTI 4Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results 2ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 2ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 3
(Date:11/26/2009)... Whitehead researchers have developed a new type ...ific genes and proteins used by pathogens, accordi...cell cultures genes are present in two copies: one.... Gene inactivation by mutation is therefore ineff...econd copy usually remains active and takes over. ...
(Date:11/26/2009)...ococcus Aureus ) and other drug-resistant bacteria... prototype devices have been developed to offer sa...ls. , Two prototype devices have been developed:....g. hands and feet) in hospitals and public spaces...her to shoot bacteria-killing agents into infested...
(Date:11/25/2009)...tomach, may be used to boost resistance to, or slo...hool of Medicine researchers report in a study pub...cience . , Parkinson,s disease is caused by a de...idbrain known as the substantia nigra, which is re...tion of dopamine in late-stage Parkinson,s causes ...
Breaking Biology News(10 mins):Knockouts in human cells point to pathogenic targets 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Hormone ghrelin can boost resistance to Parkinson's disease 2As Greenland melts 10423 1As Greenland melts 10423 2MU research team establishes family tree for cattle other ruminants 10421 1MU research team establishes family tree for cattle other ruminants 10421 2EPA fellow studies effect of mercury in toads 10419 1EPA fellow studies effect of mercury in toads 10419 2
...hagic fever have been reported in Angola. Of these...irst 6 cases, bringing the number of affected prov...ern part of the country. , Mobile surveillance tea...rday when vehicles were attacked and damaged by lo...no surveillance teams were operational today in th...
...ns researchers report that two proteins best known...her to turn the liver into a sugar-producing facto...tion of sugar is a damaging problem in people with...rget for future drugs to fight the disease, the re...liver,s production of sugar is a back-up plan that...
...ns researchers report that two proteins best known...her to turn the liver into a sugar-producing facto...tion of sugar is a damaging problem in people with...rget for future drugs to fight the disease, the re...liver,s production of sugar is a back-up plan that...
Other Biology News:WHO suspends Marburg work, appeals for new funds 2Computational verification of protein-protein interactions by orthologous co-expression 2Computational verification of protein-protein interactions by orthologous co-expression 3Future diabetes drugs may target new protein interaction 2Future diabetes drugs may target new protein interaction 3
Custom Human Cytokine Antibody Array, Choose from hundreds of proteins. from Raybiotech, Inc.
Goat Anti-Mouse Ig + IgM Antibody, FITC Conjugated from Cayman Chemical
CopyControl Induction Solution from EPICENTRE Biotechnologies
RNase III from Ambion
Biology Products: